Barinthus Biotherapeutics Plc (BRNS) Live Share Price, Invest From India

Barinthus Biotherapeutics Plc Stock Performance

as on October 18, 2025 at 1:29 am IST

Day's Low
Day's High
$1.23
Day's Price Range
$1.5
$1.34
8.21%
Downside
11.94%
Upside
52 Week's Low
52 Week's High
$0.64
52-Week Price Range
$2.92
$1.34
52.24%
Downside
117.91%
Upside

Barinthus Biotherapeutics Plc share price movements today

Previous Close: $1.35
Open: $1.35
Volume: 625.7K
Day's Low - High: $1.23 - $1.5
52 Week Low - High: $0.64 - $2.92

Barinthus Biotherapeutics Plc Historical Returns

1 Month Return: + 20.54 %
3 Month Return: -11.06 %
1 Year Return: + 8.29 %
3 Year Return: 0 %
5 Year Return: 0 %

Barinthus Biotherapeutics Plc Stock Fundamentals & Key Indicators

Check Barinthus Biotherapeutics Plc market cap, PE, PB, PEG ratios, dividend yield, and other key fundamental indicators.

Market Cap

$55.1M

EPS (TTM)

-1.63

Dividend Yield

0.00%

Quarterly Earnings Growth YOY

0.00%

PE Ratio (TTM)

-0.71

Industry PE ratio

PEG Ratio

EBITDA

-50.3M

Revenue (TTM)

15.0M

Profit Margin

0.00%

Return On Equity TTM

1580900.00%

Barinthus Biotherapeutics Plc Stock Valuation

Track how Barinthus Biotherapeutics Plc P/E has moved over time to understand its valuation trends.

Barinthus Biotherapeutics Plc in the last 5 years

Overview
Trends

Lowest (-1.63x)

December 31, 2023

Industry (0.00x)

October 18, 2025

Today (-0.71x)

October 18, 2025

Highest (-0.61x)

June 30, 2025

LowHigh

Today’s Price to Earnings Ratio: -0.71x

Barinthus Biotherapeutics Plc vs Peer Comparison

Compare market cap, revenue, PE, and other key metrics of Barinthus Biotherapeutics Plc with its industry peers.

Company	Analyst View	Market Cap	5 Years Return %	PE Ratio	Profit Margin %
Barinthus Biotherapeutics Plc	BUY	$55.1M	NA	-0.71	0.00%
Alnylam Pharmaceuticals, Inc.	BUY	$63.1B	231.27%	-505.15	-12.96%
Beone Medicines Ltd	NA	$36.7B	NA	NA	-3.89%
Vertex Pharmaceuticals Incorporated	BUY	$104.8B	91.13%	29.04	31.86%
Regeneron Pharmaceuticals, Inc.	BUY	$60.3B	-3.62%	14.35	31.37%

Stock Returns calculator for Barinthus Biotherapeutics Plc Stock including INR - Dollar returns

The Barinthus Biotherapeutics Plc stock calculator helps Indian investors calculate returns based on the historical performance of the stock. Just choose your investment amount and duration to get insights and invest more confidently. See stock returns as well as the effect of dollar appreciation over different durations.

*Dollar Return is the profit earned when the US dollar rises in value compared to the Indian rupee.

Investment Value

₹1,00,000

Barinthus Biotherapeutics Plc investment value today

Current value as on today

₹1,13,738

Returns

₹13,738

(+13.74%)

Returns from Barinthus Biotherapeutics Plc Stock

₹8,943 (+8.94%)

Dollar Returns*

₹4,794 (+4.79%)

Analyst Recommendation on Barinthus Biotherapeutics Plc Stock

Based on 12 analysts

BUY

83.33%

Buy

16.67%

Hold

0.00%

Sell

Based on 12 analysts, 83.33% of analysts recommend a 'BUY' rating for Barinthus Biotherapeutics Plc. Average target price of $5

Barinthus Biotherapeutics Plc Share Price Target

Get share price movements and forecasts by analysts on Barinthus Biotherapeutics Plc.

What analysts predicted

73.2%UPSIDE

Target Price

Current Price

$1.34

Analyzed by

12 Analysts

Target

$5.00

Barinthus Biotherapeutics Plc target price $5, a slight upside of 73.2% compared to current price of $1.34. According to 12 analysts rating.

Barinthus Biotherapeutics Plc Stock’s Investor Sentiment and Interest

Search interest for Barinthus Biotherapeutics Plc Stock has increased by 157% in the last 30 days, reflecting an upward trend in search activity.

Time period: September 18, 2025 to October 18, 2025

Change:157% versus previous 30 day period

Barinthus Biotherapeutics Plc Quarterly Profit & Loss

All numbers in Millions USD

	Mar 2023	Jun 2023	Sep 2023	Dec 2023	Mar 2024	Jun 2024	Sep 2024	Dec 2024	Mar 2025	Jun 2025
Total Revenue	0	0	-	5	-	-	14	-9	-	-
Gross Profit	0	-1	-1	3	-1	-1	14	-12	-2	-2
Operating Income	-21	-26	-16	-19	-16	-18	-9	46	-20	-23
EBITDA	-17	-23	-13	-16	-14	-15	-6	-19	-17	-19
Interest Expense	2	0	0	0	0	0	0	0	0	0
Depreciation	1	1	1	1	1	1	1	1	2	2
Income Before Tax	-18	-24	-14	-18	-15	-16	-8	-19	-19	-21
Income Tax Expense	0	-1	0	0	0	0	0	0	0	0
Net Income	-18	-23	-14	-17	-15	-16	-8	-20	-19	-21
Net Profit Margin	-3884.62%	-7126.35%	0.00%	-322.09%	0.00%	0.00%	-54.21%	223.81%	0.00%	0.00%

Barinthus Biotherapeutics Plc Annual Profit & Loss

All numbers in Millions USD

	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Total Revenue	6	4	0	44	0	14
Gross Profit	6	4	0	44	-4	14
Operating Income	-25	-20	-45	-4	-83	-67
EBITDA	-22	-14	-47	6	-71	-55
Interest Expense	0	3	2	0	0	0
Depreciation	-	0	0	4	5	5
Income Before Tax	-22	-17	-51	0	-76	-61
Income Tax Expense	-2	0	0	-4	-3	0
Net Income	-20	-17	-50	5	-73	-61
Net Profit Margin	-302.85%	-367.27%	-18979.48%	11.95%	-9145.51%	-408.00%

Barinthus Biotherapeutics Plc Quarterly Cash Flow

All numbers in Millions USD

	Jun 2023	Sep 2023	Dec 2023	Mar 2024	Jun 2024	Sep 2024	Dec 2024	Mar 2025	Jun 2025
Net Income	-23	-14	-17	-15	-16	-2	-20	-19	-21
Operating Cash Flow	-16	-11	-19	-11	-12	-18	13	-14	-18
Investing Cash Flow	-3	0	0	0	0	0	0	0	0
Financing Cash Flow	0	0	0	0	0	0	0	0	0
Change in Cash	-18	-12	-18	-12	-12	-11	6	-11	-12

Barinthus Biotherapeutics Plc Annual Cash Flow

All numbers in Millions USD

	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Net Income	-17	-51	5	-73	-61
Operating Cash Flow	-11	-32	-14	-50	-28
Investing Cash Flow	0	-12	-5	-5	0
Financing Cash Flow	41	222	0	1	2
Change in Cash	31	170	-19	-52	-29

Global Institutional Holdings in Barinthus Biotherapeutics Plc

Funds	Holdings
M&G PLC	12.88%
Alphabet Inc	3.75%
SC China Holding Ltd	3.52%
DC Funds, LP	1.59%
Baird Financial Group, Inc.	0.48%

See all

Insights on Barinthus Biotherapeutics Plc

Insights help you understand the recent movement of the company's critical parameters, giving you an overall view of the company.

POSITIVE IMPACT
Price Rise
In the last 1 month, BRNS stock has moved up by 20.5%
NO EFFECT
Against Peers
In the last 3 years, Alnylam Pharmaceuticals, Inc. has given 148.2% return, outperforming this stock by 201.6%
NO EFFECT
Against Peers
In the last 1 year, Alnylam Pharmaceuticals, Inc. has given 62.8% return, outperforming this stock by 54.5%
NEGATIVE IMPACT
Profit Down
Netprofit is down for the last 2 quarters, -19.64M → -21.12M (in $), with an average decrease of 7.5% per quarter
NEGATIVE IMPACT
Revenue Fall
Revenue is down for the last 2 quarters, 14.96M → -9.17M (in $), with an average decrease of 161.3% per quarter

About Barinthus Biotherapeutics Plc

vaccitech is a spin-out company from the university of oxford’s jenner institute, one of the oldest and most renowned vaccine research centres in the world. the company has been formed around two viral vector vaccines, one to prevent influenza and the other to treat prostate cancer. viral vector vaccines are particularly good at treating some of the most recalcitrant illnesses. the underlying technology is built on years of experience perfecting viral vector vaccine technology across multiple indications. the company’s protected chimpanzee adenovirus technology is the best way to generate t-cell responses and thereby generate lasting cell-mediated immunity. the assets are already in the clinic with very promising initial results. the founders of the company are professor adrian hill (director of the jenner institute) and professor sarah gilbert (lead in influenza and mers), who combine their exceptional scientific skills with regulatory and manufacturing experience. this autumn, vaccit

Organisation	Barinthus Biotherapeutics Plc
Headquarters	Zeus Building, Didcot, United Kingdom, OX11 0DF
CEO	Mr. William J. Enright MBA
E-voting on shares	Click here to vote

Key Management of Barinthus Biotherapeutics Plc

Name	Title
Dr. Geoffrey Lynn M.D., Ph.D.	Chief Scientific Officer
Dr. Leon Hooftman M.D.	Chief Medical Officer
Mr. William J. Enright MBA	CEO, Director & Principal Financial Officer
Ms. Gemma Brown	Principal Accounting Officer
Ms. Sarah Gilbert	Co-Founder
Mr. Adrian Hill Ph.D.	Co-Founder & Scientific Advisor

FAQs

What is Barinthus Biotherapeutics Plc share price today?

Barinthus Biotherapeutics Plc share price today is $1.34 as on October 18, 2025 at 1:29 am IST at the close of the market. Barinthus Biotherapeutics Plc share today touched a day high of $1.5 and a low of $1.23.

What is the 52 week high and 52 week low for Barinthus Biotherapeutics Plc share?

Barinthus Biotherapeutics Plc share touched a 52 week high of $2.92 on July 16, 2025 and a 52 week low of $0.64 on April 10, 2025. Barinthus Biotherapeutics Plc stock price today i.e. October 18, 2025 at 1:29 am IST is closed at $1.34,which is 54.11% down from its 52 week high and 109.38% up from its 52 week low.

What is Barinthus Biotherapeutics Plc's market capitalisation today?

Barinthus Biotherapeutics Plc market capitalisation is $0.00T as on October 18, 2025 at 1:29 am IST.

How to invest in Barinthus Biotherapeutics Plc Stock (BRNS) from India?

Step 1: Open a free US stocks account on INDmoney App and transfer your Rupees into Dollars to your INDmoney US stocks account. For a step by step instruction, check How to Transfer Money to Your US Stocks Account .
Step 2: Search for Barinthus Biotherapeutics Plc on INDmoney app. Click on Buy button. You can invest as low as $1.5 in Barinthus Biotherapeutics Plc Shares that will get you 1.1194 shares as per Barinthus Biotherapeutics Plc share price of $1.34 per share as on October 18, 2025 at 1:29 am IST.

What is the minimum amount required to buy Barinthus Biotherapeutics Plc Stock (BRNS) from India?

Indian investors can start investing in Barinthus Biotherapeutics Plc (BRNS) shares with as little as ₹87.954 or $1 (as of October 18, 2025 at 5:42 pm IST) using the INDmoney app.
For example: If you want to invest $10 or ₹879.54 in Barinthus Biotherapeutics Plc stock (as per the Rupee-Dollar exchange rate as on October 18, 2025 at 5:42 pm IST). Based on Barinthus Biotherapeutics Plc share’s latest price of $1.34 as on October 18, 2025 at 1:29 am IST, you will get 7.4627 shares of Barinthus Biotherapeutics Plc. Learn more about fractional shares .